Shandong Boan Biotechnology CDE IND application accepted for BA2201
Shandong Boan Biotechnology said its CDE IND application has been accepted for the TLLA/IL-23 bispecific antibody BA2201.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.